{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:45:08Z","timestamp":1790721908612,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Duke\u2019s The Preston Robert Tisch Brain Tumor Center","award":["Duke Glioma Translational Fund"],"award-info":[{"award-number":["Duke Glioma Translational Fund"]}]},{"name":"Duke\u2019s The Preston Robert Tisch Brain Tumor Center","award":["the Zachem Family Fund"],"award-info":[{"award-number":["the Zachem Family Fund"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse intrinsic pontine gliomas (DIPGs) are high-grade tumors of the brainstem that often occur in children, with a median overall survival of less than one year. Given the fact that DIPGs are resistant to chemotherapy and are not amenable to surgical resection, it is imperative to develop new therapeutic strategies for this deadly disease. The p53 pathway is dysregulated by<jats:italic>TP53<\/jats:italic>(~\u200960%) or<jats:italic>PPM1D<\/jats:italic>gain-of-function mutations (~\u200930%) in DIPG cases. PPM1D gain-of-function mutations suppress p53 activity and result in DIPG tumorigenesis. While MDM2 is a major negative regulator of p53, the efficacy of MDM2 inhibitor has not been tested in DIPG preclinical models. In this study, we performed a comprehensive validation of MDM2 inhibitor RG7388 in patient-derived DIPG cell lines established from both<jats:italic>TP53<\/jats:italic>wild-type\/<jats:italic>PPM1D<\/jats:italic>-mutant and<jats:italic>TP53<\/jats:italic>mutant\/<jats:italic>PPM1D<\/jats:italic>wild-type tumors, as well in<jats:italic>TP53<\/jats:italic>knockout isogenic DIPG cell line models. RG7388 selectively inhibited the proliferation of the<jats:italic>TP53<\/jats:italic>wild-type\/<jats:italic>PPM1D<\/jats:italic>mutant DIPG cell lines in a dose- and time-dependent manner. The anti-proliferative effects were p53-dependent. RNA-Seq data showed that differential gene expression induced by RG7388 treatment was enriched in the p53 pathways. RG7388 reactivated the p53 pathway and induced apoptosis as well as G1 arrest. In vivo, RG7388 was able to reach the brainstem and exerted therapeutic efficacy in an orthotopic DIPG xenograft model. Hence, this study demonstrates the pre-clinical efficacy potential of RG7388 in the<jats:italic>TP53<\/jats:italic>wild-type\/<jats:italic>PPM1D<\/jats:italic>mutant DIPG subgroup and may provide critical insight on the design of future clinical trials applying this drug in DIPG patients.<\/jats:p>","DOI":"10.1186\/s40478-021-01270-y","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T10:03:08Z","timestamp":1635933788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["TP53 wild-type\/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist"],"prefix":"10.1186","volume":"9","author":[{"given":"Cheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula K.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill H.","family":"Diplas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Waitkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9509-8431","authenticated-orcid":false,"given":"Hai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fonc.2012.00205","volume":"2","author":"KE Warren","year":"2012","unstructured":"Warren KE (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2:205","journal-title":"Front Oncol"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD (2015) DIPG in children\u2014what can we learn from the past? Front Oncol 5:237","journal-title":"Front Oncol"},{"issue":"7","key":"1270_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","volume":"9","author":"C Jones","year":"2012","unstructured":"Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9(7):400\u2013413","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1270_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40272-013-0033-5","volume":"15","author":"R Kebudi","year":"2013","unstructured":"Kebudi R, Cakir FB (2013) Management of diffuse pontine gliomas in children: recent developments. Paediatr Drugs 15(5):351\u2013362","journal-title":"Paediatr Drugs"},{"issue":"3","key":"1270_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251\u2013253","journal-title":"Nat Genet"},{"issue":"3","key":"1270_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439\u2013447","journal-title":"Acta Neuropathol"},{"issue":"7384","key":"1270_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226\u2013231","journal-title":"Nature"},{"issue":"5","key":"1270_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46(5):444\u2013450","journal-title":"Nat Genet"},{"issue":"3","key":"1270_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1309\/AJCPABOHBC33FVMO","volume":"139","author":"GH Gielen","year":"2013","unstructured":"Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T (2013) H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 139(3):345\u2013349","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"1270_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1270_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/ng.2995","volume":"46","author":"L Zhang","year":"2014","unstructured":"Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J et al (2014) Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet 46(7):726\u2013730","journal-title":"Nat Genet"},{"issue":"5","key":"1270_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor KR, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46(5):457\u2013461","journal-title":"Nat Genet"},{"issue":"5","key":"1270_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46(5):451\u2013456","journal-title":"Nat Genet"},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1038\/ncomms11185","volume":"7","author":"H Nikbakht","year":"2016","unstructured":"Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M et al (2016) Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 7:11185","journal-title":"Nat Commun"},{"issue":"4","key":"1270_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520","journal-title":"Cancer Cell"},{"issue":"7","key":"1270_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/1541-7786.MCR-19-0507","volume":"18","author":"ZH Wang","year":"2020","unstructured":"Wang ZH, Xu C, Diplas BH, Moure CJ, Chen CPJ, Chen LH et al (2020) Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib. Mol Cancer Res 18(7):968\u2013980","journal-title":"Mol Cancer Res"},{"issue":"6","key":"1270_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/neuonc\/noz053","volume":"21","author":"MP Akamandisa","year":"2019","unstructured":"Akamandisa MP, Nie K, Nahta R, Hambardzumyan D, Castellino RC (2019) Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. Neuro Oncol 21(6):786\u2013799","journal-title":"Neuro Oncol"},{"issue":"14","key":"1270_CR18","first-page":"993","volume":"1","author":"T Iwakuma","year":"2003","unstructured":"Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res 1(14):993\u20131000","journal-title":"Mol Cancer Res"},{"issue":"4","key":"1270_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ccr.2007.08.033","volume":"12","author":"XB Lu","year":"2007","unstructured":"Lu XB, Ma O, Nguyen TA, Joness SN, Oren M, Donehower LA (2007) The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12(4):342\u2013354","journal-title":"Cancer Cell"},{"issue":"14","key":"1270_CR20","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"QJ Ding","year":"2013","unstructured":"Ding QJ, Zhang ZM, Liu JJ, Jiang N, Zhang J, Ross TM et al (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56(14):5979\u20135983","journal-title":"J Med Chem"},{"issue":"21","key":"1270_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/blood.V124.21.116.116","volume":"124","author":"K Yee","year":"2014","unstructured":"Yee K, Martinelli G, Vey N, Dickinson MJ, Seiter K, Assouline S et al (2014) Phase 1\/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). Blood 124(21):116","journal-title":"Blood"},{"issue":"15","key":"1270_CR22","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/jco.2014.32.15_suppl.2535","volume":"32","author":"LL Siu","year":"2014","unstructured":"Siu LL, Italiano A, Miller WH, Blay JY, Gietema JA, Bang YJ et al (2014) Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. J Clin Oncol 32(15):2535","journal-title":"J Clin Oncol"},{"issue":"12","key":"1270_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H et al (2017) Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet 49(12):1779","journal-title":"Nat Genet"},{"issue":"44","key":"1270_CR24","doi-asserted-by":"publisher","first-page":"76644","DOI":"10.18632\/oncotarget.19656","volume":"8","author":"C Xu","year":"2017","unstructured":"Xu C, Liu XQ, Geng YB, Bai QR, Pan CC, Sun Y et al (2017) Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget 8(44):76644\u201376655","journal-title":"Oncotarget"},{"issue":"3","key":"1270_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11060-012-0973-6","volume":"110","author":"R Hashizume","year":"2012","unstructured":"Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR et al (2012) Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neuro-Oncol 110(3):305\u2013313","journal-title":"J Neuro-Oncol"},{"issue":"7","key":"1270_CR26","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.18632\/oncotarget.24045","volume":"9","author":"M Tsoli","year":"2018","unstructured":"Tsoli M, Liu J, Franshaw L, Shen H, Cheng C, Jung M et al (2018) Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget 9(7):7541\u20137556","journal-title":"Oncotarget"},{"issue":"6","key":"1270_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso CS, Tang YJ, Truffaux N, Berlow NE, Liu LN, Debily MA et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21(6):555\u2013559","journal-title":"Nat Med"},{"issue":"W1","key":"1270_CR28","doi-asserted-by":"publisher","first-page":"W537","DOI":"10.1093\/nar\/gky379","volume":"46","author":"E Afgan","year":"2018","unstructured":"Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M et al (2018) The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res 46(W1):W537\u2013W544","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1270_CR29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/bioinformatics\/btw623","volume":"33","author":"M Alhamdoosh","year":"2017","unstructured":"Alhamdoosh M, Ng M, Wilson NJ, Sheridan JM, Huynh H, Wilson MJ et al (2017) Combining multiple tools outperforms individual methods in gene set enrichment analyses. Bioinformatics 33(3):414\u2013424","journal-title":"Bioinformatics"},{"issue":"1","key":"1270_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1158\/1078-0432.CCR-18-1580","volume":"25","author":"A Berberich","year":"2019","unstructured":"Berberich A, Kessler T, Thome CM, Pusch S, Hielscher T, Sahm F et al (2019) Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib. Clin Cancer Res 25(1):253\u2013265","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1270_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.molmed.2010.09.002","volume":"16","author":"C Dai","year":"2010","unstructured":"Dai C, Gu W (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16(11):528\u2013536","journal-title":"Trends Mol Med"},{"issue":"6","key":"1270_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/138161211795222603","volume":"17","author":"H Shen","year":"2011","unstructured":"Shen H, Maki CG (2011) Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Design 17(6):560\u2013568","journal-title":"Curr Pharm Design"},{"issue":"5","key":"1270_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1215\/15228517-2008-043","volume":"10","author":"KA Bradley","year":"2008","unstructured":"Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G et al (2008) Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children\u2019s oncology group phase I study. Neuro Oncol 10(5):752\u2013758","journal-title":"Neuro Oncol"},{"issue":"11","key":"1270_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/cancers10110396","volume":"10","author":"L Skalniak","year":"2018","unstructured":"Skalniak L, Kocik J, Polak J, Skalniak A, Rak M, Wolnicka-Glubisz A et al (2018) Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells. Cancers 10(11):396","journal-title":"Cancers"},{"issue":"12","key":"1270_CR35","doi-asserted-by":"publisher","first-page":"10207","DOI":"10.18632\/oncotarget.3504","volume":"6","author":"LD Chen","year":"2015","unstructured":"Chen LD, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J et al (2015) Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget 6(12):10207\u201310221","journal-title":"Oncotarget"},{"key":"1270_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0482-3","author":"A Laroche-Clary","year":"2017","unstructured":"Laroche-Clary A, Chaire V, Algeo MP, Derieppe MA, Loarer FL, Italiano A (2017) Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-017-0482-3","journal-title":"J Hematol Oncol"},{"issue":"41","key":"1270_CR37","doi-asserted-by":"publisher","first-page":"69779","DOI":"10.18632\/oncotarget.19266","volume":"8","author":"M Zanjirband","year":"2017","unstructured":"Zanjirband M, Curtin N, Edmondson RJ, Lunec J (2017) Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget 8(41):69779\u201369796","journal-title":"Oncotarget"},{"issue":"1","key":"1270_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1570159X14666160223121002","volume":"15","author":"AL Bredlau","year":"2017","unstructured":"Bredlau AL, Dixit S, Chen C, Broome AM (2017) Nanotechnology applications for diffuse intrinsic pontine glioma. Curr Neuropharmacol 15(1):104\u2013115","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1270_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1570159X14666160614093615","volume":"15","author":"ZP Zhou","year":"2017","unstructured":"Zhou ZP, Singh R, Souweidane MM (2017) Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol 15(1):116\u2013128","journal-title":"Curr Neuropharmacol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-021-01270-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T05:57:47Z","timestamp":1699768667000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-021-01270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1186\/s40478-021-01270-y","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were approved by the Institutional Animal Care and Use Committee of Duke University (accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), International).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.Y. is the chief scientific officer and has owner interest in Genetron Holdings, and receives royalties from Genetron, Agios, and Personal Genome Diagnostics (PGDX).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}